In this issue:
Mechanism-based criteria to improve therapeutic outcomes in progressive MS
Identification of early neurodegenerative pathways in progressive MS
High prevalence of EBV associated with MS
Contribution of relapses to disability worsening in MS
DMF vs IFNβ-1a in POMS
Efficacy and safety of temelimab in MS
Clinical perspective on pain in MS
Diagnosis and management of fatigue in MS
Cortical lesion hotspots and disability in MS
Long-term management of MS patients treated with cladribine
Please login below to download this issue (PDF)